| Item Type | Name |
|
Academic Article
|
Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes?
|
|
Academic Article
|
Malignant head and neck paragangliomas: is there an optimal treatment strategy?
|
|
Concept
|
Paraganglioma, Extra-Adrenal
|
|
Concept
|
Paraganglioma
|
|
Academic Article
|
Genetic testing in head and neck paraganglioma: who, what, and why?
|
|
Academic Article
|
A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma.
|
|
Academic Article
|
Succinate dehydrogenase gene mutations are strongly associated with paraganglioma of the organ of Zuckerkandl.
|
|
Academic Article
|
Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
|
|
Academic Article
|
Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma.
|
|
Academic Article
|
Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies.
|
|
Academic Article
|
Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience.
|
|
Academic Article
|
Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
|
|
Academic Article
|
Paraganglioma syndrome type 1 in a patient with Carney-Stratakis syndrome.
|
|
Academic Article
|
Metastatic pheochromocytoma and paraganglioma: focus on therapeutics.
|
|
Academic Article
|
Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma.
|
|
Academic Article
|
Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma.
|
|
Academic Article
|
A novel SDHB mutation associated with hereditary head and neck paraganglioma.
|
|
Academic Article
|
Impact of surgical resection for subdiaphragmatic paragangliomas.
|
|
Academic Article
|
Succinate dehydrogenase gene mutations in cardiac paragangliomas.
|
|
Academic Article
|
Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma.
|
|
Academic Article
|
Functional imaging for pheochromocytoma-paraganglioma: a step closer to understanding its place in clinical practice.
|
|
Academic Article
|
Metastatic sympathetic paraganglioma in a patient with loss of the SDHC gene.
|
|
Academic Article
|
Genetic testing in head and neck paraganglioma
|
|
Academic Article
|
Succinate Dehydrogenase Gene Mutations in Cardiac Paragangliomas
|
|
Academic Article
|
Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma.
|
|
Academic Article
|
Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials.
|
|
Academic Article
|
Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.
|
|
Academic Article
|
Treatment for Malignant Pheochromocytomas and Paragangliomas: 5?Years of Progress.
|
|
Academic Article
|
Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma.
|
|
Academic Article
|
Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer.
|
|
Academic Article
|
Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors.
|
|
Academic Article
|
Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma.
|
|
Academic Article
|
Targeted Radionuclide Therapy for Patients with Metastatic Pheochromocytoma and Paraganglioma: From Low-Specific-Activity to High-Specific-Activity Iodine-131 Metaiodobenzylguanidine.
|
|
Academic Article
|
Metastatic pheochromocytoma and paraganglioma: Management of endocrine manifestations, surgery and ablative procedures, and systemic therapies.
|
|
Academic Article
|
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop.
|
|
Academic Article
|
High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease.
|
|
Academic Article
|
Antiangiogenic therapies for pheochromocytoma and paraganglioma.
|
|
Academic Article
|
Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas.
|
|
Academic Article
|
A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature.
|
|
Academic Article
|
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma.
|
|
Academic Article
|
Endocrine and Neuroendocrine Tumors Special Issue-Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?
|
|
Academic Article
|
New Directions in Treatment of Metastatic or Advanced Pheochromocytomas and Sympathetic Paragangliomas: an American, Contemporary, Pragmatic Approach.
|
|
Academic Article
|
Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma.
|
|
Academic Article
|
TNM Staging and Overall Survival in Patients With Pheochromocytoma and Sympathetic Paraganglioma.
|
|
Academic Article
|
Functional Imaging Evidence of Tumor Response to High-Specific-Activity 131 I-MIBG Therapy in an 84-Year-Old Patient With Metastatic Pheochromocytoma/Paraganglioma.
|
|
Academic Article
|
Proposed MIBG Scan-Based Tumor Response Criteria of High-Specific-Activity 131 I-MIBG Therapy in Metastatic Pheochromocytoma/Paraganglioma.
|
|
Academic Article
|
Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial.
|